Search

Your search keyword '"Frederick, Dennie T"' showing total 705 results

Search Constraints

Start Over You searched for: Author "Frederick, Dennie T" Remove constraint Author: "Frederick, Dennie T"
705 results on '"Frederick, Dennie T"'

Search Results

51. Supplementary Figure S2 from Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance

52. Data from ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma

53. Supplementary Methods, Figure Legends from Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance

57. Supplementary Figure S6 from Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2

58. Supplementary Table 3 from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

59. Data from The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNFα

60. Supplementary Table 2 from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

61. Data from Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance

62. Data from SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth

63. Supplementary Movie 2 (SM2) from Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2

64. Supplementary Figures from ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma

66. Supplementary Materials and Methods from A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

67. Supplementary Movie 1 from SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth

68. Supplementary Figure Legend from Elucidating Distinct Roles for NF1 in Melanomagenesis

69. Supplementary Figures S1 - S9, Table S1 from The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNFα

70. Data from Elucidating Distinct Roles for NF1 in Melanomagenesis

71. Supplementary Table 2 from SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth

72. Supplementary Table 4 from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

73. Supplementary Table 1 from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

74. Supplementary Tables 1 through 3 and Supplementary Figures 1 through 4 from Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

75. Supplementary Table 6 from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

76. Supplementary Movie 1 (SM1) from Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2

77. Supplementary Movie 2 from SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth

78. Data from Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2

79. Supplementary Figures from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

80. Supplementary Figure 1 from Elucidating Distinct Roles for NF1 in Melanomagenesis

81. Supplementary Figures S1-S19 from A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

82. Data from A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

83. Supplementary Movie 1 from ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma

84. Supplementary Data Figure Legends from Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2

85. Data from Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

86. Data from Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade

87. Supplementary Movie 2 from ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma

88. Supplementary Table 3 from SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth

89. Supplementary Table 1 from SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth

90. Data Supplement from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

91. Supplementary tables from ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma

92. Supplementary Table 5 from MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

93. Supplementary Table 2 from Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2

94. Supplementary Tables S1-S2 from A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

95. Supplementary Figure Legend from Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade

96. Supplementary Data from SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth

97. Supplementary Figures from Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade

98. Data from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance

99. Table S5 from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance

100. Supplementary Figures from Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance

Catalog

Books, media, physical & digital resources